Resources from the same session
515MO - Encorafenib + cetuximab (EC) + FOLFIRI for BRAF V600E-mutant metastatic colorectal cancer (mCRC): Updated results from the BREAKWATER safety lead-in (SLI)
Presenter: Josep Tabernero
Session: Mini oral session: GI tumours, lower
Resources:
Abstract
Slides
Webcast
516MO - Zanidatamab (Zani) + chemotherapy (CT) in first-line (1L) human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic colorectal cancer (mCRC)
Presenter: Sun Young Rha
Session: Mini oral session: GI tumours, lower
Resources:
Abstract
Slides
Webcast
518MO - Update analysis of the randomized phase II study comparing FOLFIRI plus ramucirumab (RAM) versus FOLFOXIRI plus RAM as first-line treatment for patients with metastatic colorectal cancer: WJOG9216G (RECAST)
Presenter: Kentaro Yamazaki
Session: Mini oral session: GI tumours, lower
Resources:
Abstract
Slides
Webcast
Invited Discussant 515MO, 516MO and 518MO
Presenter: Claire Gallois
Session: Mini oral session: GI tumours, lower
Resources:
Slides
Webcast
508MO - Organ preservation in early rectal adenocarcinoma: 5-year results of the randomized opera trial
Presenter: Syrine Ben Dhia
Session: Mini oral session: GI tumours, lower
Resources:
Abstract
Slides
Webcast
510MO - Long-term survival and organ preservation with pembrolizumab in localized MSI-H/dMMR solid tumors
Presenter: Kaysia Ludford
Session: Mini oral session: GI tumours, lower
Resources:
Abstract
Slides
Webcast
Invited Discussant 508MO and 510MO
Presenter: Dirk Arnold
Session: Mini oral session: GI tumours, lower
Resources:
Webcast
511MO - Third line rechallenge with cetuximab (Cet) and irinotecan in circulating tumor DNA (ctDNA) selected metastatic colorectal cancer (mCRC) patients: The randomized phase II CITRIC trial
Presenter: Cristina Santos Vivas
Session: Mini oral session: GI tumours, lower
Resources:
Abstract
Slides
Webcast
513MO - Amivantamab plus FOLFOX or FOLFIRI in metastatic colorectal cancer: Results from OrigAMI-1, an open-label, phase Ib/II study
Presenter: Filippo Pietrantonio
Session: Mini oral session: GI tumours, lower
Resources:
Abstract
Slides
Webcast
514MO - The efficacy and safety of ivonescimab with or without ligufalimab in combination with FOLFOXIRI as first-line (1L) treatment for metastatic colorectal cancer (mCRC)
Presenter: Yanhong Deng
Session: Mini oral session: GI tumours, lower
Resources:
Abstract
Slides
Webcast